Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial of Y-2 Sublingual Tablet in the Treatment of Acute Ischemic Stroke - a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial

NCT04950920 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04950920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial of Y-2 Sublingual Tablet in the Treatment of Acute Ischemic Stroke - a Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial
Lead sponsor
Peking University Third Hospital
Phase
Phase 3
Overall status
Completed
Start date
June 28, 2021
Completion date
November 14, 2022
Enrollment
914 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stroke